Stimulated to death

Stimulated to death

Peptimmune Inc. is targeting the CD4 T cells responsible for driving the production of the auto-antibodies that cause pemphigus vulgaris (PV). While not a booming indication, the disease characteristics make it attractive for such a therapy. And with $41.2 million in fresh capital announced last week, the spinout from Genzyme General (GENZ) is ready to enter the clinic(see Ebb & Flow, A19). ...